Literature DB >> 3674848

Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria.

J L Whiting1, N Cheng, A W Chow.   

Abstract

A total of 598 clinical isolates of anaerobic bacteria were tested against ciprofloxacin by the agar dilution technique with 10(5) CFU on Wilkins-Chalgren medium. Selected strains representative of the six major genera of anaerobes relatively resistant to the quinolones were tested for interactions with ciprofloxacin in combination with clindamycin, metronidazole, cefoxitin, cefotaxime, or mezlocillin by using a checkerboard agar dilution technique. Cefotaxime-ciprofloxacin and clindamycin-ciprofloxacin were the most effective combinations, with 16% of all isolates and 44% of the Bacteroides fragilis group isolates responding synergistically to the former combination and 9% of all isolates and 37% of Peptostreptococcus isolates responding synergistically to the latter. Occasional synergy was seen with all other antibiotic combinations except for metronidazole-ciprofloxacin. Likewise, synergism was seen with all groups of anaerobes except for Fusobacterium species. Antagonistic interactions were observed only with a Peptostreptococcus intermedius strain tested against clindamycin-ciprofloxacin. These data suggest that combinations of ciprofloxacin with these agents may be useful for certain resistant anaerobic infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3674848      PMCID: PMC174946          DOI: 10.1128/AAC.31.9.1379

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Comparative activity of ciprofloxacin against anaerobic bacteria.

Authors:  V L Sutter; Y Y Kwok; J Bulkacz
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

2.  Susceptibility of Legionella spp. to quinolone derivatives and related organic acids.

Authors:  G Ruckdeschel; W Ehret; A Ahl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

3.  In vitro activity of ciprofloxacin against clinical isolates of Chlamydia trachomatis.

Authors:  H Meier-Ewert; G Weil; G Millott
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

4.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

5.  Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria.

Authors:  M V Borobio; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.

Authors:  L J Chalkley; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

8.  Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains.

Authors:  I Haller
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  Tissue penetration of ciprofloxacin after single and multiple doses.

Authors:  M LeBel; F Vallée; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

View more
  13 in total

Review 1.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.

Authors:  D J Walters; J S Solomkin; J A Paladino
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 4.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 6.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 7.  Newly documented antimicrobial activity of quinolones.

Authors:  Y X Furet; J C Pechère
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 8.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

9.  Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.

Authors:  J S Solomkin; H H Reinhart; E P Dellinger; J M Bohnen; O D Rotstein; S B Vogel; H H Simms; C S Hill; H S Bjornson; D C Haverstock; H O Coulter; R M Echols
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

10.  In vitro activities of three of the newer quinolones against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.